Impact of the adherence to medical treatment on the main urinary metabolic disorders in patients with kidney stones

Braulio Omar Manzo a,*, Jose David Cabrera a, Esteban Emiliani b, Hector Manuel Sánchez a, Brian Howard Eisner c, Jose Ernesto Torres a

a Urology Department, Hospital Regional de Alta Especialidad del Bajío, Blvd. Milenio #130, Col. San Carlos la Roncha, León, Guanajuato, Mexico
b Urology Department, Fundación Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain
c Urology Department, Massachusetts General Hospital, Harvard Medical School, Boston, USA

Received 9 November 2019; received in revised form 6 January 2020; accepted 1 June 2020
Available online 6 August 2020

Abstract  Objective: To assess the effect of the adherence to medical treatment on urinary parameters in the 24-h metabolic study of patients with kidney stones.
Methods: A retrospective, longitudinal, descriptive, and observational study was carried out by reviewing the hospital electronic medical record from 2014 to 2018. The adherence to drug treatment was measured 6 months after its initiation, and the numerical values of the metabolic studies were compared. Wilcoxon tests were performed to compare the difference before and after treatment.
Results: Ninety patients were evaluated, with 73.3% of adherence. The 180-day overall adherence rate was 61.2% in patients treated with a single drug and 85.4% in patients treated with multiple drugs. There is a statistically significant increase in citrate levels in patients with good adherence in comparison with non-adherent patients (p=0.031 vs. p=0.528).
Conclusions: Medical treatment and dietary measures in patients with kidney stones have an initial impact at 6 months on the values of the main urinary metabolic alterations that predispose to calculi formation; the most significant is seen in those patients with adherence to medical treatment for hypocitraturia.

© 2021 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The recurrence rate of renal stones is about 50% at 5-year follow-up if pharmacologic treatment is not given [1–3]. The most critical factors that contribute to calcium stones formation are hypercalciuria, hypocitraturia, hyperuricosuria, and hyperoxaluria [4,5]. Nowadays, the 24-hour urine collection is the gold standard method to identify such abnormalities to guide the pharmacological treatment and dietary modifications [6].

Adherence to an established treatment is defined as the extent to which patients take medications prescribed by their healthcare providers. Also, adherence is a cornerstone for an adequate response and resolution of any human disease like all metabolic disorders responsible for kidney stones [7–10]. Additionally, adherence is a crucial gauge of health care quality, and nonadherence is associated with poor health outcomes and substantial economic costs [11]. Despite the above, nonadherence to drug therapy is one of the main limitations in the treatment of chronic diseases, reducing the benefits that could be obtained [12]. Efforts to accurately measure and improve adherence have received increasing attention from patients, physicians, payers, and all the rest of health care stakeholders.

Unfortunately, today there is no consensus standard for what adequate adherence constitutes and how to measure it adequately. A 50% adherence rate has been described for chronic illness such as hypertension and type 2 diabetes in a 6-month follow-up [13]. Prior studies on this topic have reported a 70% compliance rate for stone patients followed explicitly in a comprehensive kidney stone center. It is likely that compliance for the typical patient, in a non-specialized center, is significantly lower [14]. Therefore, the purpose of the current study was to describe the patients’ compliance rates to the stone prevention regimens and to evaluate its influence in the 24-hour urine parameters at 6 months of follow-up.

2. Methods

A retrospective cohort study was conducted, with a longitudinal, descriptive, and observational design approved by the ethics committee with the registration number (CI/HRAEB/2019/040). From 2014 to 2018, we analyzed all adult patients with kidney stones diagnosis and stone-free state after their surgical procedure. All patients had two metabolic studies, including 24-hour urine panel and urinary pH determination in single sample separately with dipstick (Chemstrip® by Roche Diagnostics, Indianapolis, USA), and a reflectance photometer (Urisys 1100, Diagnostics, Laval QC): The first one performed at the time of determining stone-free status and the second in the follow-up after medical intervention at 6 months. Medical treatment was directed depending on the patient’s metabolic abnormality in the first metabolic evaluation. We defined hypocitraturia as urine citrate of <320 mg/day, hyperoxaluria as a urine oxalate of >0.4 mmol/day, hypercalciuria >200 mg/day and hyperuricosuria as a urine uric acid of >0.7 g/day. All patients received a printed sheet with the dietary recommendations corresponding to each metabolic alteration. Standardized treatment regimen were as follows: For hypocitraturia were given potassium citrate (KCit) 2 g PO BID bid; for hypercalciuria were given hydrochlorothiazide (HCT) 25 mg PO QD; for hyperuricosuria were given allopurinol (Allo) 300 mg PO QD, and finally, hyperoxaluria was managed with low oxalate/calcium-rich diet [15]. For patients with two or more alterations of 24-hour urine composition, they received multiple treatments with two or more prescriptions, as well as combined dietary modifications (Supplementary material). Compliance or adherence to dietary modifications was evaluated by self-reported dietary compliance as described by previous authors [16,17].

2.1. Determination of adherence

Adherence to drug treatment was determined by reviewing the electronic medical record. To estimate adherence, we use the formula for the proportion of days covered (PDC) described by Dauw et al. [18]. The PDC is calculated as the number of days covered by a specific drug divided by the total number of days in the follow-up period. For patients taking more than one medication, we estimated the adherence by calculating the average class-specific PDC values. We used a follow-up period of 180 days after the first drug prescription in our study, and then we multiplied the PDC by 100 to express it as a percentage. According to previous studies, we defined a good adherence if this percentage was equal or greater than 80%. Patients with less than 80% and those who lost the prescription or had irregular follow-up were considered as having poor adherence.

2.2. Statistical analysis

The program used for statistical purposes was IBM SPSS version 25 (IBM Corp., Armonk, NY). A univariate analysis was carried out using frequencies and percentagess for categorical data and measures of central tendency and corresponding dispersion according to the distribution of the data in the quantitative variables, following the Kolmogorov-Smirnov normality test. Wilcoxon tests were performed to compare the difference before and after medical treatment. A p<0.05 and a 95% bilateral confidence interval were considered statistically significant.

3. Results

Ninety patients met inclusion criteria (i.e., stone-free status after surgery and at least 180 days of follow-up for metabolic stone evaluation and treatment). The demographic data of the 90 patients are presented in Table 1. The relative prevalence of the 24-hour urine abnormalities, taking into account that many patients had more than one disorder, was as follows: Hypocitraturia (41.26%), hyperuricosuria (14.28%), hypercalciuria (16.40%) and hyperoxaluria (28.04%) (see Table 1).

Of the 90 patients included in this study, 36 (40%) were treated with monotherapy (single drug); the most frequent treatment was KCit (n=29), followed by HCT (n=7) and no single patient had monotherapy treatment with allopurinol. Forty-one (45.5%) patients were treated with multi-drug
The impact of adherence to medical treatment

4. Discussion

Adherence to medical treatment is a complicated issue to evaluate. Some strategies to evaluate this include surveying the patients, directly observing medication taking, measuring drug or metabolites in plasma/urine, or using electronic medication monitors. Previous studies evaluating compliance used the self-reporting patients (directly surveying the patients) being the simplest to achieve and considered to be reliable in the published literature [11,12]. Similar to Dauw et al. [18], we evaluated patient’s adherence to the proportion of days formula in order to evaluate the impact of the adherence to medical treatment and dietary modifications on the primary metabolic disorders that predispose to stone formation in patients diagnosed with kidney stones.

Reducing recurrence is the main objective of preventive treatment, and it should be individualized concerning the specific metabolic alteration of each patient. Thiazides are the standard management for idiopathic hypercalciuria; compared to placebo, a significant decrease in stone recurrence (more than 60% of reduction) has been documented [15]. Hypocitraturia is treated by alkali therapy. The most frequent combination was KCit+HCT (n=12), KCit+Allo (n=9), KCit+HCT+Allo (n=8), HCT+Allo (n=6), KCit+Mg (n=3), Cit+Calcitriol (n=3).

Thirteen (14.4%) patients with hyperoxaluria were managed just with dietary therapy. The 180-day overall adherence rate was 73.3% (61.2% in patients treated with a single drug and 85.4% in patients treated with multiple drugs). The overall differences in the urine parameters of patients after pharmacologic treatment are shown in Table 2.

Finally, in those patients with hyperoxaluria, there was a decrease of 12% in calcium levels. In those patients with hypercalciuria, there was a decrease of 25% in uric acid levels. In those patients with hypercalciuria, there were no changes in the urine oxalate levels. However, neither adherent nor non-adherent patients demonstrated a statistically significant difference in urinary parameters at six-month follow-up (p=non significant for all). These results are shown in Tables 3 and 4.

Table 1 Baseline and demographic characteristics.

| Characteristics | Patients | Percentage (%) |
|-----------------|----------|----------------|
| Gender, n       |          |                |
| Male            | 50       | 55.6           |
| Female          | 40       | 44.4           |
| Age (year)      | 45.4 (13.2)* |                |
| DM2, n          | 8        | 8.9            |
| HTN, n          | 25       | 27.8           |
| BMI (kg/m²)     | 28.8 (4.3)* |                |
| Normal, n       | 17       | 18.9           |
| Overweight, n   | 42       | 46.7           |
| Grade I Obesity, n | 30    | 33.3           |
| Grade II Obesity, n | 1     | 1.1            |
| Stone volume (mm²) | 252 (124–447.3)* |          |
| Number of Stones, n | 2 (1–3)* |                |
| Urinary Metabolic Disorders, n |         |                |
| Hypocitraturia  | 78       | 41.26          |
| Hyperoxaluria   | 53       | 28.04          |
| Hypercalciuria  | 31       | 16.40          |
| Hyperuricosuria | 27       | 14.28          |

DM2, Type II Diabetes; HTN, hypertension; BMI, body mass index.

* Mean (Standard Deviation).

Table 2 Differences between the first metabolic study and its control 6 months after the start of medical treatment.

| Metabolic disorder | Before, mean (range) | After, mean (range) | p-Value |
|--------------------|----------------------|---------------------|---------|
| Hypocitraturia (n=78) |                       |                     |         |
| Urinary pH         | 6 (5–7)              | 6 (5.5–6.75)        | 0.473   |
| 24 h urine Cit (mg/d) | 62 (20.5–208)        | 189 (40–274)        | 0.015*  |
| 24 h volume (mL)   | 1900 (1485–2585)     | 2210 (1600–2740)    | 0.561   |
| Hyperuricosuria (n=27) |                       |                     |         |
| Urinary pH         | 6 (5.5–6.7)          | 6 (5.5–6.8)         | 0.606   |
| 24 h urine UA (g/d) | 0.8 (0.5–10)         | 0.7 (0.5–0.9)       | 0.021*  |
| 24 h volume (mL)   | 2100 (1780–2800)     | 2145 (1500–2970)    | 0.764   |
| Hypercalciuria (n=31) |                       |                     |         |
| Urinary pH         | 6 (5.3–6.5)          | 6 (5.8–6.5)         | 0.425   |
| 24 h urine Ca (mg/d) | 302.4 (172.2–367.4)  | 261.8 (208–342)     | 0.854   |
| 24 h volume (mL)   | 2200 (1720–2970)     | 2360 (1700–2920)    | 0.984   |
| Hyperoxaluria (n=53) |                       |                     |         |
| 24 h urine Ox (mmol/d) | 0.6 (0.5–0.8)        | 0.6 (0.5–0.8)       | 0.906   |
| 24 h volume (mL)   | 2390 (1845–2950)     | 2440 (1800–2965)    | 0.468   |

*Statistically significant. Wilcoxon tests were performed to compare the difference before and after medical treatment. A p<0.05 and a 95% bilateral confidence interval were considered statistically significant.
preparations based on citrate and has been shown to maintain stone-free rates of 92% in surveillance vs. 58% in placebo patients [19]. Allopurinol has been indicated for the treatment of calcium oxalate stones associated with hyperuricosuria; its use has shown up to a 50% decrease in the recurrence of lithiasis vs. placebo [20]. In hyperoxaluria, the reduction of dietary oxalate is essential; only 52% of patients have adequate compliance with dietary measures and fluid consumption, achieving a significant decrease in urinary oxalate levels [16, 21, 22].

In the current study, we found that adherence to prescribed measures described above resulted in significant differences in 24-hour urine composition only in patients taking potassium citrate. At first glance, this is somewhat surprising, considering that hypercalciuric patients received a thiazide diuretic and hyperuricosuric patients received allopurinol. We feel that the best possible explanation for these findings is likely the diet that is typical of the region in Mexico where our patients come. This diet is a diet rich in sodium and animal protein. Sodium is known to reduce or block the hypocalciuric effects of thiazide diuretics, and a diet rich in animal protein may result in increased urinary uric acid excretion and reduce the uric acid lowering effects of allopurinol. On the other hand, these dietary tendencies would not be expected to reduce the effects of potassium citrate, which works by causing systemic alkalization, inducing citrate excretion into the urine. Another finding to assess was that urinary pH did not change significantly after potassium citrate treatment, as is commonly expected. We use the urine dipstick (Urissys® by Roche) as the pH determination evaluation method, and it has been described that this kind of study (photometry readers) has considerable inaccuracy that could cause bias in our results [23].

In our study, 73.3% (61.2% in single drug and 85.4% with multiple drugs) of patients showed adherence to medical treatment and dietary recommendations. This adherence rate is a high percentage compared to the reported in previous studies. One possible explanation for the high adherence of our population is that the majority of patients treated in our center (a tertiary referral center for complex stone disease) have experienced recurrent or persistent complicated urinary stones. Therefore, our patients may be highly motivated to comply with preventive measures and treatments that were given. Additionally, opposite to previous studies, our patients submitted to multiple therapies for more than one metabolic alteration, showed higher compliance. A big concern, suffering, and even the loss of one renal unit could be one reason for this high adherence in patients with multiple metabolic diagnoses, but this needs to be further studied. Nonetheless, we observed, as described above, that adherence to therapy only resulted in significant changes in patients with hypocitraturia.

These findings may be unique to our patient population. As described above, there exists level 1 evidence that each of the three medication therapies: Potassium citrate, thiazide diuretics, and allopurinol results in a significant reduction in recurrent stone events. However, these studies were all performed in a distinct population (United States) where dietary habits may be different from those of our patients [20, 24, 25]. We feel that our findings have significant implications for the treatment of patients in Mexico with recurrent calcium oxalate stone disease. One could assume if future studies confirm these findings, that the optimal medication for stone prevention for patients in this region of Mexico would be potassium citrate-based therapies.

Our study has several limitations, which are inherent in a retrospective study, such as the definition of adherence. As reported in previous studies, it is not possible to assess accurately if the patient took or not the medication, despite the records in the file and pharmacy. Previous studies have been based on self-patient reporting to measure compliance or adherence to medical treatment and dietary measures. Also, non-adherent patients could have taken another dietary or herbal treatments not reported to doctors that could affect their metabolic profile. The study was conducted in a third level hospital, with a specialized lithiasis clinic, in which complex and recurrent cases of kidney stones are treated so that it could be not representative of the general population. Although the follow-up time of our population could be considered a short time

| Table 3 | Changes showed in the 24-hour urine parameters in patients with adherence to medical and dietary treatment. |
|----------|---------------------------------------------------------------|
| Metabolic alteration | Variable | Before, mean (range) | After, mean (range) | p-Value |
| Hypocitraturia (n=78) | 24 h Cit (mg/d) | 60 (18–191.5) | 141.5 (29.2–274) | .031* |
| Hyperuricosuria (n=27) | 24 h UA (g/d) | 0.8 (0.4–22.6) | 0.6 (0.4–0.9) | .088 |
| Hypercalcuiuira (n=31) | 24 h Ca (mg/d) | 297.5 (167.7–366.9) | 261.8 (191.7–342.0) | .889 |
| Hyperoxaluria (n=53) | 24 h Ox (mmol/d) | 0.6 (0.5–0.8) | 0.6 (0.4–0.7) | .286 |

*Statistically significant. Wilcoxon tests were performed to compare the difference before and after medical treatment. A p<0.05 and a 95% bilateral confidence interval were considered statistically significant.

| Table 4 | Changes showed in the 24-hour urine parameters in patients with no adherence to medical and dietary treatment. |
|----------|---------------------------------------------------------------|
| Metabolic alteration | Variable | Before, mean (range) | After, mean (range) | p-Value |
| Hypocitraturia (n=78) | 24 h Cit (mg/d) | 32 (18–322) | 248.5 (80.7–281.5) | .528 |
| Hyperuricosuria (n=27) | 24 h UA (g/d) | 0.8 (0.6–5.9) | 0.7 (0.6–4.9) | .327 |
| Hypercalcuiuira (n=31) | 24 h Ca (mg/d) | 305.1 (226.1–305.1) | 228.7 (213.2–228.7) | .655 |
| Hyperoxaluria (n=53) | 24 h Ox (mmol/d) | 0.4 (0.3–0.7) | 0.6 (0.5–0.8) | .374 |
follow-up for chronic diseases, all the previous studies evaluating adherence to medical treatment have reported just 6 months of follow-up [16–18]. Long-term follow-up is necessary to document the constancy to adherence in chronic treatments and to observe changes in the 24-hour urinary metabolic study and its long-term effect on recurrence rate changes, stone re-formation, emergency visits, and even loss of kidney function.

5. Conclusion

Medical treatment and dietary measures in patients with kidney stones have an initial impact at 6 months on the values of the main urinary metabolic alterations that predispose to calculus formation; the most significant is seen in those patients with adherence to medical treatment for hypocitraturia.

Author contributions

Study concept and design: Jose Ernesto Torres, Braulio Omar Manzo, Jose David Cabrera.

Data acquisition: Jose Ernesto Torres, Jose David Cabrera.

Data analysis: Jose Ernesto Torres, Braulio Omar Manzo, Esteban Emiliani, Hector Manuel Sánchez, Brian Howard Eisner.

Drafting of manuscript: Jose Ernesto Torres, Braulio Omar Manzo, Esteban Emiliani, Hector Manuel Sánchez.

Critical revision of the manuscript: Braulio Omar Manzo, Esteban Emiliani, Brian Howard Eisner.

Conflicts of interest

The authors declare no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ajur.2020.07.002

References

[1] Pearle MS, Antonelli JA, Lotan Y. Urinary lithiasis: etiology, epidemiology, and pathogenesis. In: Campbell–walsh urology. 11th ed. Elsevier Inc; 2019. p. 1170–99.
[2] Rule AD, Lieske JC, Li X, Melton 3rd LJ, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol 2014;25:2878–86.
[3] Medina-Escobedo M, Zaidi M, Real-de León E, Orozco-Rivadeneyra S. Urolithiasis prevalence and risk factors in Yucatan, Mexico. Salud Publica Mex 2002;44:541–5 [Article in Spanish].
[4] Coe FL, Kavalach AG. Hypercalcuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 1974;291:1344–50.
[5] Pak CY, Nicar M, Northcutt C. The definition of the mechanism of hypercalcuria is necessary for the treatment of recurrent stone formers. Contrib Nephrol 1982;33:136–51.
[6] Corder CJ, Leslie SW. 24-Hour urine collection [Updated 2020 May 27]. [Internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482482/.
[7] Pak CY. Etiology and treatment of urolithiasis. Am J Kidney Dis 1991;18:624–37.
[8] Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77–84.
[9] Parks JH, Goldfischer E, Asplin JR, Coe FL. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol 2002;167:1607–12.
[10] Ostenberg L, Blaschke T. Adherence to medication. NEJM 2005;353:487–97.
[11] Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care 2009;15:457–64.
[12] Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary non-adherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence 2018;12:721–31.
[13] De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs 2003;2:323. https://doi.org/10.1016/S1474-5151(03)00091-4.
[14] Parks JH, Asplin JR, Coe FL. Patient adherence to long-term medical treatment of kidney stones. J Urol 2001;166:2057–60.
[15] Eisner BH, Goldfarb DS, Pareek G. Pharmacologic treatment of kidney stone disease. Urol Clin North Am 2013;40:21–30.
[16] Hennessey DB, Kinnear N, Rice G, Curry D, Woolsey S, Duggan B. Compliance in patients with dietary hyperoxaluria: a cohort study and systematic review. Asian J Urol 2019;6:200–7.
[17] Dauw CA, Yi Y, Bierlein MJ, Yan P, Alruwaily AF, Ghani KR, et al. Factors associated with preventive pharmacological therapy adherence among patients with kidney stones. Urology 2016;93:45–9.
[18] Dauw CA, Yi Y, Bierlein MJ, Yan P, Alruwaily AF, Ghani KR, et al. Medication nonadherence and effectiveness of preventive pharmacological therapy for kidney stones. J Urol 2016;195:648–52.
[19] Zisman AL. Effectiveness of treatment modalities on kidney stone recurrence. Clin J Am Soc Nephrol 2017;12:1699–708.
[20] Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386–9.
[21] Siener R, Schade N, Nicolay C, Von Unruh GE, Hesse A. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients. J Urol 2005;173:1601–5.
[22] Pak CY, Sakkhae K, Crowther C, Brinkley L. Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann Intern Med 1980;93:36–9.
[23] Ilyas R, Chow K, Young JG. What is the best method to evaluate urine pH? A trial of three urinary pH measurement methods in a stone clinic. J Endourol 2015;29:70–4.
[24] Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2069–73.
[25] Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988;139:679–84.